Mannkind, Game-Chancer in Sachen Diabetik? (Seite 151)
eröffnet am 11.01.11 13:02:26 von
neuester Beitrag 03.04.24 20:06:55 von
neuester Beitrag 03.04.24 20:06:55 von
Beiträge: 6.825
ID: 1.162.683
ID: 1.162.683
Aufrufe heute: 4
Gesamt: 593.771
Gesamt: 593.771
Aktive User: 0
ISIN: US56400P7069 · WKN: A2DMZL · Symbol: NNFN
3,8820
EUR
-0,61 %
-0,0240 EUR
Letzter Kurs 15.04.24 Tradegate
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3.000,00 | +74.900,00 | |
| 2,9400 | +73,96 | |
| 2,4700 | +33,51 | |
| 0,8890 | +19,96 | |
| 5,4900 | +17,06 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,4000 | -20,27 | |
| 1,8100 | -23,95 | |
| 1,4300 | -24,34 | |
| 7,7200 | -25,34 | |
| 1,7900 | -59,87 |
Beitrag zu dieser Diskussion schreiben
Feedback
Wochenumsatz: 1,14 Millionen US Dollar, wird schön langsam, mit big partner locker das fünfache drin!
höre auf stocktwits
TRX 703
DYOR
TRX 703
DYOR
Antwort auf Beitrag Nr.: 60.284.154 von Magnetfeldfredy am 05.04.19 07:27:29Seh ich auch so, auf Nasdaq.com kann man schön sehen wer in den letzten 3-12 Mon. gekauft bzw. verkauft hat.
Einfach mal schauen
Einfach mal schauen
Es ist eine zähe Geschichte aber der UTHR-Deal mit den jüngsten Meilensteinzahlungen läßt mich hoffen auf weitere Deals und höhere Kurse!
Antwort auf Beitrag Nr.: 60.279.441 von sir1 am 04.04.19 17:23:06
Bin ich etwa der CEO oder IR-Abteilung von Mannkind??
Bin ich etwa der CEO oder IR-Abteilung von Mannkind?? Trading Spotlight
Antwort auf Beitrag Nr.: 60.272.253 von pegasusorion am 04.04.19 07:03:04wo bleiben die Erfolge....zahlen facts news where ist it?
Sag ich doch, der Chart stimmt auch hier wies aussieht :-)
Konsolidierung durch???
Todgesagte leben länger und Mannind wird mit der Technosphere Technologie auferstehen wie Phönix aus der Asche:
ind Receives $12.5 Million Milestone Payment from United Therapeutics
GlobeNewswire•April 1, 2019
WESTLAKE VILLAGE, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today announced that it achieved the first of several specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil. Treprostinil Technosphere (“TreT”) is an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension. Pursuant to the agreement, MannKind is eligible to earn additional payments up to $37.5 million upon the achievement of other defined development milestones. MannKind will also be entitled to receive low double-digit royalties on net sales of TreT.
MannKind also announced that it filed a new shelf registration statement on Form S-3 with the Securities and Exchange Commission on March 29, 2019, which, when effective, will replace the existing shelf registration statement that expires on April 27, 2019.
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S.
For further information, visit www.mannkindcorp.com.
ind Receives $12.5 Million Milestone Payment from United Therapeutics
GlobeNewswire•April 1, 2019
WESTLAKE VILLAGE, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today announced that it achieved the first of several specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil. Treprostinil Technosphere (“TreT”) is an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension. Pursuant to the agreement, MannKind is eligible to earn additional payments up to $37.5 million upon the achievement of other defined development milestones. MannKind will also be entitled to receive low double-digit royalties on net sales of TreT.
MannKind also announced that it filed a new shelf registration statement on Form S-3 with the Securities and Exchange Commission on March 29, 2019, which, when effective, will replace the existing shelf registration statement that expires on April 27, 2019.
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S.
For further information, visit www.mannkindcorp.com.
News, einfach mal auf Nasdaq.com unter Mannkind oder auf die Unternehmensseite schaun---Meilenstein :-)
Durchsuchen
Mannkind, Game-Chancer in Sachen Diabetik?
